7:33AM NuPathe nnounced the Company will present data on ZECUITY; Patients who had migraine-related nausea at the time of treatment were nearly twice as likely to report their headache pain (PATH) 2.84 : This was a post-hoc analysis of the randomized, parallel-group, double-blind, placebo-controlled Phase 3 clinical trial data to compare the efficacy of ZECUITY in relieving migraine headache pain and associated symptoms in patients who had nausea at baseline compared with patients who did not report nausea as a symptom at baseline. Patients who had migraine-related nausea at the time of treatment were nearly twice as likely to report their headache pain as "severe" than those without MRN at the time of treatment (31% vs. 16%).
The data showed that ZECUITY was efficacious in treating migraine headache pain and associated symptoms regardless of the presence of nausea prior to treatment. This was a post-hoc analysis of the randomized, parallel-group, double-blind, placebo-controlled Phase 3 clinical trial data to compare the incidence of treatment-emergent nausea two hours after patch activation in patients treated with ZECUITY or placebo who were nausea free at the beginning of treatment. The data showed that at two hours following patch activation, patients treated with a placebo patch (13.8%) were three times more likely to have treatment-emergent nausea as those treated with ZECUITY (4.6%). In addition, the data showed that the incidence of treatment-emergent nausea with ZECUITY was lower than placebo from one hour through 24 hours following patch activation.
Market Data 
Markets 
AI
